Cancer Medicines Forum: March 2026
EventHumanMedicines
Swedish is available via eTranslation, the European Commission's machine translation service.
Translate to Swedish | Important information about machine translation
Date
- måndag, 2 mars 2026, Hela dagen
Plats
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
Event summary
Setting up in March 2022, the Cancer Medicines Forum (CMF) was created by EMA in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) with the overall goal to optimise cancer treatments.
The meeting in March 2026 focuses on the following topics:
- An analysis of late life-cycle innovation in medicines, focusing on post-launch indication expansion was presented. Dose optimisation appears relatively uncommon in later-life indications and that value assessments should be interpreted in the context of evolving standards of care. The potential benefits of integrating optimisation earlier in the development process were emphasised, alongside the regulatory expectation that dosing is generally established at the time of marketing authorisation, while recognising the continued role of post-authorisation optimisation.
- Paediatric and young adult (AYA) oncology: regulators' and clinicians' perspective: the EMA outlined key considerations to improve evidence generation for adolescents and young adults (AYA) with cancer. EORTC provided an overview of the current state of science in AYA oncology, highlighting variability in definitions and care organisation across countries.
- CMF composition and governance structure: the EMA presented the proposed composition and governance structure of the CMF following its formalisation under the Healthcare Professionals' and Patients' and Consumers' Working Parties. The framework foresees four categories of participation: members, advisors, observers, and invited guests, aimed at ensuring balanced and flexible stakeholder input across relevant groups.
- Follow-up from November 2025 CMF–industry meeting: the EMA presented a proposed action plan outlining priority thematic areas for future work. The objective is to prioritise topics that may be advanced in the short term into structured outputs. Priority areas include treatment optimisation, incentives to support optimisation research, collaborative industry–academia models, data sharing and tissue banks, improved approaches to assessing toxicity and benefit, and best practices for pragmatic clinical trials in oncology.